Gene: IFNL3 ×
Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE Patients with early virologic response (HCV RNA <25 IU/mL [detectable/undetectable in IL28B CC patients or undetectable in IL28B CT/TT patients] at Week 2 and undetectable at Weeks 4 and 8) were eligible to stop all treatment at the end of Week 12, otherwise PR therapy was continued to Week 24. 28056030 2017
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 Biomarker disease BEFREE Noncirrhotic, IL28B CC patients with HCV genotype 1 infection were randomized to GZR 100 mg once daily and RBV for 12 or 24 weeks. 27291249 2016
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE Levels of ISGs and IFNL2/3 mRNAs were lower in IFNL3 rs12979860 CC patients compared with non-CC patients, and in treatment responders, compared with nonresponders. 26020282 2016
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. 27140229 2016
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE Sofosbuvir achieves higher SVR rates than simeprevir except for treatment-naïve IL28B CC patients and naïve HCV genotype 1b patient. 25396710 2015
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE In HCV-genotype 1/4 (n=25), none of the patients with CT or TT IL28B genotype achieved SVR compared to 50% of the CC patients (p=0.004). 26114179 2015
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 Biomarker disease BEFREE 11/11 (100%) and 19/22 (86.4%) IL28B CC patients achieved SVR in the ESRD and control groups, respectively. 25987772 2015
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 Biomarker disease BEFREE SOF was cost-effective compared with BOC in all strategies with the exception of cirrhosis and IL28B CC patients. 24691835 2014
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 Biomarker disease BEFREE IL28B CC phenotype was associated with increased probability of achieving eRVR and SVR, whereas previous non-response was associated with low eRVR and SVR rates. 24612466 2014
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE The correlation between IL28B.rs12979860 genotypes and CMI is suggestive of a possible important role of CMI in favoring hepatitis C virus clearance in CC patients. 23784926 2013
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 Biomarker disease BEFREE To identify baseline and on-therapy predictors of treatment failure in HCV-1 IL28B CC patients. 23936821 2013
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE These data may provide some mechanistic explanation for higher rate of SVR in IL28B CC patients who are treated with PEG-IFN/RBV. 22313623 2012
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 Biomarker disease BEFREE 64% of IL28B-CC patients showed a sustained virological response. 22711348 2012
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE Among IL28B-CC patients (n = 196), the rs429358 (defines ε4 isoform) and TOMM40 '523' S polymorphisms were associated with 12 % of variance in ApoB levels. 22898894 2012
Entrez Id: 282617
Gene Symbol: IFNL3
IFNL3 		0.100 GeneticVariation disease BEFREE In the antifibrotic study, steatosis was found in 47.6% (50/105) of IL28B non-CC vs. 22.5% (9/40; p=0.008) in CC patients. 21703198 2011